Matches in DBpedia 2016-04 for { ?s ?p "Enzyme potentiated desensitization, or EPD, is a treatment for allergies developed in the 1960s by Dr. Len McEwen in the United Kingdom. EPD uses much lower doses of antigens than conventional treatment, with the addition of an enzyme, β-glucuronidase. EPD is available in the United Kingdom, Canada for the treatment of hay fever, food allergy and intolerance and environmental allergies.EPD was under development for the treatment of autoimmune disease by a United Kingdom company called Epidyme also owned by Dr. McEwen which has been granted a United Kingdom patent. Despite encouraging results in an experimental model of rheumatoid arthritis the company was placed into liquidation in April 2010."@en }
Showing triples 1 to 2 of
2
with 100 triples per page.
- Enzyme_potentiated_desensitization abstract "Enzyme potentiated desensitization, or EPD, is a treatment for allergies developed in the 1960s by Dr. Len McEwen in the United Kingdom. EPD uses much lower doses of antigens than conventional treatment, with the addition of an enzyme, β-glucuronidase. EPD is available in the United Kingdom, Canada for the treatment of hay fever, food allergy and intolerance and environmental allergies.EPD was under development for the treatment of autoimmune disease by a United Kingdom company called Epidyme also owned by Dr. McEwen which has been granted a United Kingdom patent. Despite encouraging results in an experimental model of rheumatoid arthritis the company was placed into liquidation in April 2010.".
- Q5381548 abstract "Enzyme potentiated desensitization, or EPD, is a treatment for allergies developed in the 1960s by Dr. Len McEwen in the United Kingdom. EPD uses much lower doses of antigens than conventional treatment, with the addition of an enzyme, β-glucuronidase. EPD is available in the United Kingdom, Canada for the treatment of hay fever, food allergy and intolerance and environmental allergies.EPD was under development for the treatment of autoimmune disease by a United Kingdom company called Epidyme also owned by Dr. McEwen which has been granted a United Kingdom patent. Despite encouraging results in an experimental model of rheumatoid arthritis the company was placed into liquidation in April 2010.".